A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adult Participant
← catalyst calendarSponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
137actual
Sites
1
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-03-14 | actual | When the study began enrolling |
| Primary completion | 2025-08-19 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-19 | actual | The whole study's end, after follow-up |
| First posted | 2024-01-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Participants
Interventions
- Drug: INCB160058
- Drug: Placebo
- Drug: Esomeprazole
- Drug: Famotidine
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with Treatment Emergent Adverse Events (TEAEs)
measured Up to Day 28
INCB160058 pharmacokinetic (PK) when administered as solid tablets in Plasma
measured Up to Day 5
INCB160058 pharmacokinetic (PK) when administered as a soft gel capsule in Plasma
measured Up to Day 5
INCB160058 pharmacokinetic (PK) when administered as ASD tablets in Plasma
measured Up to Day 5
INCB160058 pharmacokinetic (PK) in Plasma to determine the effect of food administered as solid tablets
measured Up to Day 12
INCB160058 pharmacokinetic (PK) in Plasma to determine the effect of food administered as ASD tablets
measured Up to Day 12
INCB160058 pharmacokinetic (PK) in Plasma to assess the effect of esomeprazole administered as solid tablets
measured Up to Day 14
INCB160058 pharmacokinetic (PK) in Plasma to assess the effect of esomeprazole administered as ASD tablets
measured Up to Day 14
INCB160058 pharmacokinetic (PK) in Plasma to assess the effect of famotidine administered as solid tablets
measured Up to Day 14
INCB160058 pharmacokinetic (PK) in Plasma to assess the effect of famotidine administered as ASD tablets
measured Up to Day 14
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed